[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vaneck Pharmaceutical ETF (PPH)

Vaneck Pharmaceutical ETF (PPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family Van Eck Associates
  • Assets Under Management 973,009,700
  • Shares Outstanding, K 9,490
  • 60-Month Beta 0.47
  • Price/Earnings ttm 23.67
  • Annual Dividend & Yield 2.15 (2.10%)
  • Most Recent Dividend 0.844 on 04/01/26
  • Expense Ratio 0.36%
  • INDUSTRY GROUPING:

    ETFs - Healthcare

Options Overview Details

View History
  • Implied Volatility 20.38% (-0.16%)
  • Historical Volatility 19.17%
  • IV Percentile 56%
  • IV Rank 35.91%
  • IV High 29.78% on 03/30/26
  • IV Low 15.12% on 09/03/25
  • Expected Move (DTE 28) 0.00 (0.00%)
  • Put/Call Vol Ratio 1.50
  • Today's Volume 30
  • Volume Avg (30-Day) 82
  • Put/Call OI Ratio 1.25
  • Today's Open Interest 1,101
  • Open Int (30-Day) 1,068
  • Expected Range 102.53 to 102.53

Price Performance

See More
Period Period Low Period High Performance
1-Month
100.45 +2.07%
on 06/02/26
107.95 -5.02%
on 06/11/26
+1.41 (+1.39%)
since 05/18/26
3-Month
98.25 +4.36%
on 04/29/26
107.95 -5.02%
on 06/11/26
+0.33 (+0.32%)
since 03/18/26
52-Week
81.74 +25.43%
on 08/07/25
112.58 -8.93%
on 02/17/26
+14.73 (+16.78%)
since 06/18/25

Most Recent Stories

More News
Even If Eli Lilly Stock Continues to Shine, Stay Away from This Pharmaceutical ETF

The rest of the stocks in the IHE ETF make it an unappealing way to play the pharma industry here.

IHE : 91.88 (-1.02%)
JNJ : 228.39 (-2.48%)
LLY : 1,098.57 (-1.21%)
PPH : 102.53 (-1.64%)
$DOWI : 51,564.70 (unch)
Sickly Healthcare Stocks Are Perking Up. For Contrarian Investors, Buying Now Could Be Just the Remedy to Protect Your Portfolio.

Go beyond the broad index and find which segment of healthcare best suits your portfolio needs now.

XLV : 149.40 (-0.87%)
$SPX : 7,500.58 (unch)
MRK : 113.87 (-1.36%)
LLY : 1,098.57 (-1.21%)
PPH : 102.53 (-1.64%)
IHI : 49.07 (+1.38%)
UNH : 400.96 (+0.36%)
ELV : 388.50 (-0.71%)
PFE : 25.21 (-2.74%)
Are Wall Street Analysts Bullish on Cencora Stock?

Cencora has consistently outperformed the broader market over the past year, and analysts are maintaining a strongly bullish outlook on the company’s growth and earnings potential.

$SPX : 7,500.58 (unch)
COR : 271.83 (-1.90%)
PPH : 102.53 (-1.64%)
AbbVie Stock: Is Wall Street Bullish or Bearish?

AbbVie has lagged the broader market over the past year, although Wall Street analysts remain moderately optimistic about the company’s long-term growth prospects and pipeline strength.

$SPX : 7,500.58 (unch)
PPH : 102.53 (-1.64%)
ABBV : 216.49 (-2.14%)
What Are Wall Street Analysts' Target Price for Cencora Stock?

Cencora has consistently outperformed the broader market over the past year, and analysts are maintaining a strongly bullish outlook on the company’s growth and earnings potential.

$SPX : 7,500.58 (unch)
COR : 271.83 (-1.90%)
PPH : 102.53 (-1.64%)
Cencora Stock: Is Wall Street Bullish or Bearish?

Pharma distributor Cencora has continued to outpace the broader market over the past year, and analysts remain strongly bullish on the stock’s prospects.

$SPX : 7,500.58 (unch)
COR : 271.83 (-1.90%)
PPH : 102.53 (-1.64%)
NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain

Shares of Novo Nordisk NVO climbed nearly 4% on Monday after its famous obesity drug, Wegovy, received accelerated approval from the U.S. Food and Drug Administration (FDA) to treat a serious liver disease....

NVO : 43.19 (-0.76%)
OZEM : 30.39 (-0.42%)
PPH : 102.53 (-1.64%)
THNR : 24.12 (-0.59%)
Cencora Stock: Analyst Estimates & Ratings

Cencora has outpaced the broader market over the past year, and Wall Street analysts maintain a highly optimistic outlook on the stock’s prospects.

$SPX : 7,500.58 (unch)
JPM : 325.22 (-2.47%)
COR : 271.83 (-1.90%)
PPH : 102.53 (-1.64%)
ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data

Eli Lilly and Company LLY reported robust second-quarter 2025 results, wherein it beat estimates on both the top and bottom lines, driven by strong demand for its blockbuster weight loss and diabetes drugs....

NVO : 43.19 (-0.76%)
OZEM : 30.39 (-0.42%)
IHE : 91.88 (-1.02%)
LLY : 1,098.57 (-1.21%)
MEDX : 33.88 (-1.02%)
PPH : 102.53 (-1.64%)
MEDI : 30.85 (-0.96%)
ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook

Johnson & Johnson JNJ reported stronger-than-expected second-quarter 2025 results. The world's biggest healthcare products maker continued with its long streak of earnings beat and also exceeded revenue...

XLV : 149.40 (-0.87%)
JNJ : 228.39 (-2.48%)
IHE : 91.88 (-1.02%)
IYH : 62.68 (-0.71%)
PPH : 102.53 (-1.64%)
FTXH : 35.38 (-0.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Fund Summary

The VanEck Vectors Pharmaceutical ETF seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical...

See More

Key Turning Points

3rd Resistance Point 106.48
2nd Resistance Point 105.39
1st Resistance Point 103.96
Last Price 102.53
1st Support Level 101.44
2nd Support Level 100.35
3rd Support Level 98.92

See More

52-Week High 112.58
Last Price 102.53
Fibonacci 61.8% 100.80
Fibonacci 50% 97.16
Fibonacci 38.2% 93.52
52-Week Low 81.74

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.